News - Shire

Filter

Current filters:

Shire

Popular Filters

1 to 25 of 81 results

Shire gets positive ruling on Vyvanse patents from US district court

25-06-2014

Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from…

ActavisAmneal PharmaLegalMylanNeurologicalPatentsPharmaceuticalRoxaneSandozShireUSAVyvanse

Analysts view Shire defense as independent pharma

Analysts view Shire defense as independent pharma

24-06-2014

There has been quite a lot of reaction to yesterday’s presentation by Ireland-headquartered Shire's…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire sets out robust defense for rejecting AbbVie takeover bid

Shire sets out robust defense for rejecting AbbVie takeover bid

23-06-2014

Ireland-headquartered Shire today presented a robust defense of its position as an independent pharmaceutical…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Charitable pharma companies aim to make a difference

Charitable pharma companies aim to make a difference

20-06-2014

Here's our take on the week's alternative news.

Adderall XRADHDMerck & CoShireVyvanse

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

20-06-2014

Ireland headquartered Shire has this morning revealed that it has received, and rejected, an unsolicited…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

12-06-2014

Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…

NeurologicalPharmaceuticalRegulationResearchShireUSAVyvanse

arGEN-X and Shire sign long term collaboration deal worth $20 million

arGEN-X and Shire sign long term collaboration deal worth $20 million

04-06-2014

Belgium-based preclinical stage biotech firm arGEN-X has entered into a long-term strategic alliance…

arGEN-XBiotechnologyBusiness FinanceEuropeHuman antibody discovery technologiesResearchShireShire Pharmaceuticals

Shire plans NDA filing with FDA for Lifitegrast in 1st-qtr 2015

18-05-2014

Following a May 15, 2014, meeting with the US Food and Drug Administration, Ireland-headquartered drugmaker…

LifitegrastManagementOphthalmicsPharmaceuticalRegulationShire

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Latest EU cost-effectiveness data for epilepsy finds benefits for Shire’s Buccolam

25-04-2014

New European economic modeling data published recently in Health Economics Review provides evidence demonstrating…

BuccolamEuropeFinancialHealthcareNeurologicalPharmaceuticalShire

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

19-02-2014

Ireland-headquartered drugmaker Shire has had an application for its once-daily attention deficit/hyperactivity…

ElvanseNeurologicalPharmaceuticalRegulationShire

Shire CFO Graham Hetherington to step down

Shire CFO Graham Hetherington to step down

13-02-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial…

BoardroomNorthern EuropePharmaceuticalShire

Shire posts top year-end results and expects earnings to rise again in 2014

Shire posts top year-end results and expects earnings to rise again in 2014

13-02-2014

Ireland-headquartered drugmaker Shire has recorded a rise in sales and earnings to deliver strong full-year…

DermagraftFinancialFirazyrIntunivLialdaMezavantNorthern EuropePharmaceuticalShireViroPharmaVprivVyvanse

Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III

07-02-2014

Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…

NeurologicalPharmaceuticalResearchShireVyvanse

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

23-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive…

BoardroomEuropePharmaceuticalShire

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

09-12-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced mixed results from a Phase III efficacy…

EuropeLifitegrastOphthalmicsPharmaceuticalResearchShire

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

19-11-2013

Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

1 to 25 of 81 results

Back to top